ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "axial spondyloarthritis"

  • Abstract Number: 434 • 2019 ACR/ARP Annual Meeting

    Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials

    Cheng-Chung Wei1, Theresa Hunter 2, Filip Van den Bosch 3, Jessica Walsh 4, Uta Kiltz 5, Yan Dong 6, David Sandoval 6, Luis Leon 6, Vibeke Strand 7 and Xiaoqi Li 2, 1Chung Shan Medical University, Taichung City, Taiwan (Republic of China), 2Eli Lilly and Company, Indianapolis, 3Ghent University Hospital, Ghent, Belgium, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 6Eli Lilly and Company, Indianapolis, IN, 7Division of Immunology/Rheumatology, Stanford University, Stanford, CA

    Background/Purpose: Previous trials have used the Short Form (SF)-36 questionnaire to evaluate the impact of ankylosing spondylitis/radiographic axial spondyloarthritis (AS/r-axSpA) on health-related quality of life…
  • Abstract Number: 593 • 2019 ACR/ARP Annual Meeting

    Performance of the ASAS Classification Criteria Presenting with Undiagnosed Back Pain: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort

    Walter P. Maksymowych1, Raj Carmona 2, Jonathan Chan 3, James Yeung 4, Sibel Zehra Aydin 5, Liam Martin 6, Ariel Masetto 7, Dianne Mosher 8, Olga Ziouzina 6, Stephanie Keeling 9, Sherry Rohekar 10, Rana Dadashova 11, Joel Paschke 11, Amanda Carapellucci 11 and Robert Lambert 12, 1University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, 2McMaster University, Hamilton, Canada, 3Artus Health Clinic, Vancouver, BC, Canada, 4Yeung Rheumatology, Vancouver, Canada, 5University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, 6University of Calgary, Calgary, Canada, 7Université de Sherbrooke, Sherbrooke, QC, Canada, 8University of Calgary, Calgary, AB, Canada, 9University of Alberta, Edmonton, AB, Canada, 10Western University, London, ON, Canada, 11CARE Arthritis, Edmonton, Canada, 12University of Alberta, Edmonton, Canada

    Background/Purpose: Classification criteria for axial spondyloarthritis (axSpA) that capture the spectrum of disease present challenges due to the frequency of back pain, the relative infrequency…
  • Abstract Number: 622 • 2019 ACR/ARP Annual Meeting

    Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study

    Jean Liew1, John Reveille 2, Henna Sawhney 3, Maria Castillo 3, Benjamin Naovarat 4, Susan Heckbert 1 and Lianne Gensler 5, 1University of Washington, Seattle, WA, 2University of Texas McGovern Medical School, Houston, 3University of California in San Francisco, San Francisco, CA, 4University of Texas-McGovern Medical School, Houston, TX, 5University San Francisco California, San Francisco, CA

    Background/Purpose: Cardiovascular morbidity and mortality are increased in axial spondyloarthritis (axSpA). The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high intensity statin…
  • Abstract Number: 1084 • 2019 ACR/ARP Annual Meeting

    Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration

    Lykke Midtbøll Ørnbjerg1, Stylianos Georgiadis 2, Ulf Lindström 3, Anne Gitte Loft 4, Adrian Ciurea 5, Herman Mann 6, Nurullah Akkoç 7, Florenzo Iannone 8, Eirik Kristianslund 9, Anna Mari Hokkanen 10, Maria José Santos 11, Catalin Codreanu 12, Carlos Sánchez-Piedra 13, Matija Tomsic 14, Bjorn Gudbjornsson 15, Irene van der Horst-Bruinsma 16, Johan Askling 17, Michael J. Nissen 18, Karel Pavelka 6, Ozgül Gunduz 7, Fabiola Atzeni 19, Joe Sexton 20, Dan Nordström 21, Helena Santos 22, Ruxandra IONESCU 23, Manuel Pombo-Suarez 24, Ziga Rotar 25, Arni Jon Geirsson 26, Marleen van de Sande 16, Gary Macfarlane 27, Brigitte Michelsen 28, Merete Lund Hetland 1 and Mikkel Østergaard 29, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 3University of Gothenburg, Gothenburg, Sweden, 4Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, 5University Hospital Zürich, Zürich, Switzerland, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 7Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, 8Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 9Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 10Helsinki University Hospital, Helsinki, Finland, 11Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 12Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 13Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 14Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, 15Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 16Amsterdam University Medical Center, Amsterdam, Netherlands, 17Karolinska Institutet, Stockholm, Sweden, 18University Hospital Geneva, Geneva, Switzerland, 19Department of Medicine, Messina, Italy, 20Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 21Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 22Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 23SPITALUL CLINIC SFANTA MARIA, Bucharest, 24Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 25UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 26Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 27University of Aberdeen, Aberdeen, United Kingdom, 28EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have vastly improved prognosis in patients with axial spondyloarthritis (axSpA). However, many patients treated with TNFi still fail to…
  • Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting

    Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)

    Gareth Jones1, Linda Dean 1, Ejaz Pathan 2 and Gary Macfarlane 1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Toronto Western Hospital, Toronto, Canada

    Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
  • Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting

    Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial

    Frank Behrens1, Philipp Sewerin 2, Eugenio de Miguel 3, Yusuf Patel 4, Anastas Batalov 5, Eva Dokoupilova 6, Christine Kleinmond 7, Effie Pournara 8, Ankita Shekhawat 9, Claudia Jentzsch 10, Annette Wiedon 10 and Xenofon Baraliakos 11, 1CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, 2Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 4Hull University Teaching Hospitals, Hull, United Kingdom, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, 7ClinProject GmbH, Eurasburg, Germany, 8Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, 9Novartis Healthcare Pvt. Ltd., Hyderabad, India, 10Novartis Pharma GmbH, Nürnberg, Germany, 11Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany

    Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…
  • Abstract Number: 557 • 2019 ACR/ARP Annual Meeting

    Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

    Theresa Hunter1, David Sandoval 2, Nicola Booth 3, Elizabeth Holdsworth 4 and Atul Deodhar 5, 1Eli Lilly and Company, Indianapolis, 2Eli Lilly and Company, Indianapolis, IN, 3Adelphi Real World, Bollington, United Kingdom, 4Adelphi Real World, Manchester, England, United Kingdom, 5Oregon Health & Science University, Portland, OR

    Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
  • Abstract Number: 594 • 2019 ACR/ARP Annual Meeting

    Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort

    Walter P. Maksymowych1, Raj Carmona 2, Jonathan Chan 3, James Yeung 4, Sibel Zehra Aydin 5, Liam Martin 6, Ariel Masetto 7, Dianne Mosher 8, Olga Ziouzina 6, Stephanie Keeling 9, Sherry Rohekar 10, Rana Dadashova 11, Joel Paschke 11, Amanda Carapellucci 11 and Robert Lambert 12, 1University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, 2McMaster University, Hamilton, Canada, 3Artus Health Clinic, Vancouver, BC, Canada, 4Yeung Rheumatology, Vancouver, Canada, 5University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, 6University of Calgary, Calgary, Canada, 7Université de Sherbrooke, Sherbrooke, QC, Canada, 8University of Calgary, Calgary, AB, Canada, 9University of Alberta, Edmonton, AB, Canada, 10Western University, London, ON, Canada, 11CARE Arthritis, Edmonton, Canada, 12University of Alberta, Edmonton, Canada

    Background/Purpose: xThe ASAS classification criteria for axial spondyloarthritis (axSpA) have overall sensitivity/specificity of 82.9%/84.4% but component imaging and clinical arms differ in performance (66.2%/97.3% and…
  • Abstract Number: 624 • 2019 ACR/ARP Annual Meeting

    Axial Spondyloarthritis: Knowledge, Screening and Referral Practices Amongst Primary Care Providers

    Laura Passalent1, Christopher Hawke 2, Jeff Bloom 2, Andrew Bidos 3, Soever Leslie 2, Y. Raja Rampersaud 1, Nigil Haroon 4 and Robert Inman 5, 1Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, Canada, 3University Health Network, Toronto, Canada, 4Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, 5University of Toronto, University Health Network, Toronto, ON, Canada

    Background/Purpose: Early recognition is crucial in improving outcomes in patients with axial spondyloarthritis (axSpA).  Despite this, there exists long delay between symptom onset and rheumatology…
  • Abstract Number: 1163 • 2019 ACR/ARP Annual Meeting

    Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP

    Manouk de Hooge1, Ann-Sophie De Craemer 1, Thomas Renson 1, Philippe Carron 1, Liselotte Deroo 1, Dirk Elewaut 1 and Filip Van den Bosch 1, 1Ghent University Hospital, Ghent, Belgium

    Background/Purpose: HLA-B27 and sacroiliitis on MRI form the basis of the Assessment of SpondyloArthritis international Society (ASAS) axial spondyloarthritis (axSpA) classification criteria. In addition, while…
  • Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting

    Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks

    Sergio Schwartzman1, Atul Deodhar 2, Andris Kronbergs 3, Silvia Santisteban 3, Sandra Garces 3, David Sandoval 3, Jeffrey Lisse 3, Fangyi Zhao 3, Denis Poddubnyy 4 and James Rosenbaum 5, 1The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, 2Oregon Health & Science University, Portland, OR, 3Eli Lilly and Company, Indianapolis, IN, 4Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 5Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR

    Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
  • Abstract Number: 2728 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

    Désirée van der Heijde1, In-Ho Song 2, Aileen Pangan 3, Atul Deodhar 4, Filip Van den Bosch 5, Walter P. Maksymowych 6, Tae-Hwan Kim 7, Mitsumasa Kishimoto 8, Andrea Everding 9, Yunxia Sui 10, Xin Wang 10, Alvina D. Chu 10 and Joachim Sieper 11, 1Leiden University Medical Center, Leiden, Netherlands, 2AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 3AbbVie Inc., North Chicago, 4Oregon Health & Science University, Portland, OR, 5Ghent University Hospital, Ghent, Belgium, 6University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 9HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, 10AbbVie Inc., Chicago, 11Charité Universitätsmedizin Berlin, Germany, Berlin, Germany

    Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK)…
  • Abstract Number: 678 • 2018 ACR/ARHP Annual Meeting

    Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?

    Shahla Vahidfar1, Ismihan Sunar2, Sebnem Ataman3, Gürkan Yılmaz4, Javid M. AZARABADI5 and Ayşe Bölükbaşı1, 1Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, 2Department of Physical Medicine and Rehabilitation, Division of Rheumatology,, Ankara University, Faculty of Medicine, Ankara, Turkey, 3Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, 4Physical Medicine and Rehabilitation, Rheumatology Division, Ankara University Faculty of Medicine, Ankara, Turkey, 5ORTHOPEDICS AND TRAUMATOLOGY, Başkent University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues…
  • Abstract Number: 2062 • 2018 ACR/ARHP Annual Meeting

    Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study

    Fernanda Genre1, Javier Rueda-Gotor1, Sara Remuzgo-Martínez1, Verónica Pulito-Cueto1, Alfonso Corrales1, Verónica Mijares1, Leticia Lera-Gómez1, Virginia Portilla1, Rosa Expósito2, Cristina Mata2, Iván Ferraz-Amaro3, M. Vanesa Hernandez-Hernandez4, Santos Castañeda5, Esther Vicente5, Cristina Fernández-Carballido6, María Paz Martínez-Vidal7, David Castro-Corredor8, Joaquín Anino-Fernández8, Ricardo Blanco1, Oreste Gualillo9, Javier Martin10, Javier Llorca11, Raquel Lopez-Mejías1 and Miguel Angel González-Gay1,12, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Rheumatology Division, Hospital Comarcal de Laredo, Laredo, Spain, 3Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 4Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, 5Rheumatology Division, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 6Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, 7Rheumatology Division, Hospital General Universitario de Alicante, Alicante, Spain, 8Rheumatology Division, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 9SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 10Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain, 11Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 12School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

    Background/Purpose: Cardiovascular (CV) disease (mainly due to accelerated atherosclerosis) is one of the main causes of mortality in axial spondyloarthritis (axSpA). The higher incidence of…
  • Abstract Number: 691 • 2018 ACR/ARHP Annual Meeting

    A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications

    Chong Seng Edwin Lim1, Samantha Bee Lian Low2, Baljeet Dhillon2, Shin Azegami2, Andoni Paul Toms2 and Karl Gaffney1, 1Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, 2Radiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom

    Background/Purpose: A combined service evaluation by the rheumatology and radiology department was undertaken to understand the frequency and reporting standards of Computer Tomography-defined Sacroiliitis (CTSI)…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology